Two original ADCs (ABBV-3373 and ABBV-154) containing a glucocorticoid receptor modulator (GRM) are being clinically evaluated for the treatment of rheumatoid arthritis and Crohn’s disease (Table 2, NCT03823391, NCT04888585, NCT05068284 and NCT04972968). Here, NR3C1 is linked to Crohn disease.